Literature DB >> 25762198

Bayesian path specific frailty models for multi-state survival data with applications.

Mário de Castro1, Ming-Hui Chen2, Yuanye Zhang3.   

Abstract

Multi-state models can be viewed as generalizations of both the standard and competing risks models for survival data. Models for multi-state data have been the theme of many recent published works. Motivated by bone marrow transplant data, we propose a Bayesian model using the gap times between two successive events in a path of events experienced by a subject. Path specific frailties are introduced to capture the dependence structure of the gap times in the paths with two or more states. Under improper prior distributions for the parameters, we establish propriety of the posterior distribution. An efficient Gibbs sampling algorithm is developed for drawing samples from the posterior distribution. An extensive simulation study is carried out to examine the empirical performance of the proposed approach. A bone marrow transplant data set is analyzed in detail to further demonstrate the proposed methodology.
© 2015, The International Biometric Society.

Entities:  

Keywords:  Gamma frailty; Gap time; Gibbs sampler; Piecewise exponential model; Survival analysis

Mesh:

Year:  2015        PMID: 25762198      PMCID: PMC4567543          DOI: 10.1111/biom.12298

Source DB:  PubMed          Journal:  Biometrics        ISSN: 0006-341X            Impact factor:   2.571


  16 in total

Review 1.  Multi-state models: a review.

Authors:  P Hougaard
Journal:  Lifetime Data Anal       Date:  1999-09       Impact factor: 1.588

2.  Multi-state models in epidemiology.

Authors:  D Commenges
Journal:  Lifetime Data Anal       Date:  1999-12       Impact factor: 1.588

3.  Bayesian analysis of a disability model for lung cancer survival.

Authors:  C Armero; S Cabras; M E Castellanos; S Perra; A Quirós; M J Oruezábal; J Sánchez-Rubio
Journal:  Stat Methods Med Res       Date:  2012-07-05       Impact factor: 3.021

4.  Reduced-rank proportional hazards regression and simulation-based prediction for multi-state models.

Authors:  Marta Fiocco; Hein Putter; Hans C van Houwelingen
Journal:  Stat Med       Date:  2008-09-20       Impact factor: 2.373

5.  Semi-Markov models with phase-type sojourn distributions.

Authors:  Andrew C Titman; Linda D Sharples
Journal:  Biometrics       Date:  2010-09       Impact factor: 2.571

6.  Bayesian gamma frailty models for survival data with semi-competing risks and treatment switching.

Authors:  Yuanye Zhang; Ming-Hui Chen; Joseph G Ibrahim; Donglin Zeng; Qingxia Chen; Zhiying Pan; Xiaodong Xue
Journal:  Lifetime Data Anal       Date:  2013-03-30       Impact factor: 1.588

7.  Multi-state models for the analysis of time-to-event data.

Authors:  Luís Meira-Machado; Jacobo de Uña-Alvarez; Carmen Cadarso-Suárez; Per K Andersen
Journal:  Stat Methods Med Res       Date:  2008-06-18       Impact factor: 3.021

Review 8.  Model diagnostics for multi-state models.

Authors:  Andrew C Titman; Linda D Sharples
Journal:  Stat Methods Med Res       Date:  2009-08-04       Impact factor: 3.021

9.  Multi-state models for colon cancer recurrence and death with a cured fraction.

Authors:  A S C Conlon; J M G Taylor; D J Sargent
Journal:  Stat Med       Date:  2013-12-05       Impact factor: 2.373

10.  Bayesian analysis of generalized odds-rate hazards models for survival data.

Authors:  Tathagata Banerjee; Ming-Hui Chen; Dipak K Dey; Sungduk Kim
Journal:  Lifetime Data Anal       Date:  2007-03-31       Impact factor: 1.429

View more
  2 in total

1.  A Bayesian multi-risks survival (MRS) model in the presence of double censorings.

Authors:  Mário de Castro; Ming-Hui Chen; Yuanye Zhang; Anthony V D'Amico
Journal:  Biometrics       Date:  2020-02-06       Impact factor: 2.571

Review 2.  A review of multistate modelling approaches in monitoring disease progression: Bayesian estimation using the Kolmogorov-Chapman forward equations.

Authors:  Zvifadzo Matsena Zingoni; Tobias F Chirwa; Jim Todd; Eustasius Musenge
Journal:  Stat Methods Med Res       Date:  2021-04-07       Impact factor: 3.021

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.